MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: a systematic review

被引:0
作者
Wafaa M. Rashed
Mahmoud M. Hamza
Marwa Matboli
Sherin I. Salem
机构
[1] Children’s Cancer Hospital Egypt-57357 (CCHE-57357),Clinical Trials Unit, Clinical Research
[2] Children’s Cancer Hospital Egypt-57357 (CCHE-57357),Biostatistics Unit, Clinical Research
[3] Ain Shams University,Biochemistry Department, Faculty of Medicine
[4] Children’s Cancer Hospital Egypt-57357 (CCHE-57357),Cytogenetics Department
[5] Cairo University,National Cancer Institute
来源
Cancer and Metastasis Reviews | 2019年 / 38卷
关键词
Acute lymphoblastic leukemia; MicroRNA; Prognostic biomarker;
D O I
暂无
中图分类号
学科分类号
摘要
Recent studies suggest abnormal microRNA (miRNA) expression may have potential prognostic value in childhood acute lymphoblastic leukemia (ALL). In this systematic review, we searched different databases (PubMed, ASH, ASCO, and SIOP) for studies published from 2008 to 2018 that evaluated the prognostic impact of miRNAs in childhood ALL. We also used DIANA-miRPath v3.0 to further characterize the functional role of the significant prognostic miRNAs identified in our systematic review. Here we evaluate 15 studies with a total of 38 different miRNAs and 1545 children with B-cell ALL (B-ALL) or T-cell ALL (T-ALL) recruited over approximately 3 decades (1984–2016) with different treatment protocols and ethnicities. Out of the 15 studies examined, 14 reported 32 dysregulated miRNAs with significant prognostic impact in pediatric ALL patients. Only one Brazilian study reported no significant prognostic effect of 7 miRNAs, while the seventh miRNA (miR-100) showed prognostic significance in a Chinese study. Using DIANA-TarBase v7.0 of DIANA-miRPath v3.0, pathway enrichment analysis revealed 25 miRNAs modulated 24 molecular pathways involved in cancer development. To remove the effect of salvage therapy, 9 studies carried out multivariate cox regression analysis for both relapse-free survival and disease-free survival to develop a panel of 23 miRNAs acting as independent prognostic biomarkers. To enhance the clinical application, utility, and validity of the miRNAs discussed here, their potential prognostic value should be confirmed in larger cohort studies within different ethnicities and different ALL protocols adjusted for other contemporary validated prognostic factors in childhood ALL.
引用
收藏
页码:771 / 782
页数:11
相关论文
共 190 条
[1]  
Kato M(2018)Treatment and biology of pediatric acute lymphoblastic leukemia Pediatrics International 60 4-12
[2]  
Manabe A(2014)Milestones in the curability of pediatric cancers Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 32 2391-2397
[3]  
Hudson MM(2012)Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematology. American Society of Hematology. Education Program 2012 129-136
[4]  
Link MP(2019)The potential for microRNA therapeutics and clinical research Frontiers in Genetics 10 478-718
[5]  
Simone JV(2019)MicroRNA based theranostics for brain cancer: basic principles Journal of Experimental & Clinical Cancer Research 38 231-W466
[6]  
Raetz EA(2019)Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics RNA Biology 16 707-103
[7]  
Bhatla T(2015)DIANA-miRPath v3.0: deciphering microRNA function with experimental support Nucleic Acids Research 43 W460-2520
[8]  
Hanna J(2013)Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia British Journal of Haematology 163 93-339
[9]  
Hossain GS(2012)MicroRNA profiling in pediatric acute lymphoblastic leukemia: novel prognostic tools Leukemia & Lymphoma 53 2517-4915
[10]  
Kocerha J(2016)miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia Genes, Chromosomes & Cancer 55 328-711